Novartis AG ADR
USUSDNovartis AG ADR (XETRA:NOT) — Drug Manufacturers - General. Aantal beurzen waarop de aandelen van het bedrijf worden verhandeld: 7. Op deze pagina — koers en grafiek, dividenden, grootste aandeelhouders en historiek van het aantal aandelen.
Over het bedrijf
- Website
- novartis.com
- Sector
- Healthcare · Drug Manufacturers - General
- Hoofdkantoor
- BASEL, Switzerland
- CEO
- Vasant Narasimhan
- Werknemers
- 75 267
- Opgericht
- 1996
- Uitstaande aandelen
- 1.91 mld. per 2025-12-31
- Free float
- 1.86 mld.
- Marktkapitalisatie
- 276.48 mld. USD
- Insiders
- 0.01%
- Institutionele beleggers
- 7.27%
- Branche (SIC)
- Pharmaceutical Preparations
- Rechtsvorm
- MVII
- ISIN
- CH0012005267
- LEI
- 5493007HIVTX6SY6XD66
- Uitkeringsratio
- 56.0%
- FCF
- 17.6 mld. USD44%
- Schuld
- 29.4 mld. USD1.0 jr FCF
- Dividendreeks
- 20 jr
- Winst, FCF en uitbetaalde dividenden — voor de 12 maanden tot 31.12.2025 (het laatste rapport van het bedrijf).
Beschrijving
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Beurzen en tickers
| Beurs | Ticker | Valuta | Prijs | Type |
|---|---|---|---|---|
| US USA Stocks | NVSEF OTC | USD | 139.9825 +3.12% | gewone aandelen |
| LSE London Stock Exchange | 0QLR IOB | CHF | 82.63 +0.00% | gewone aandelen |
| MI Borsa Italiana (Milan) | 1NOVN secundair | EUR | 127.94 +1.33% | gewone aandelen |
| SW SIX Swiss Exchange | NOVN primair | CHF | 119.8 -0.13% | gewone aandelen |
| SW SIX Swiss Exchange | NOVNEE secundair | CHF | 120.02 -1.80% | gewone aandelen |
| VI Vienna Stock Exchange | NOVN secundair | EUR | 127.32 -0.31% | gewone aandelen |
| XETRA Xetra | NOT secundair | EUR | 126.82 +0.48% | gewone aandelen |
Dividenden
Novartis AG ADR (NOT) keert eenmaal per jaar dividend uit. In de afgelopen 12 maanden werd 3.9091 EUR per aandeel betaald (betalingen: 1). Dat is ongeveer 3.08% van de huidige aandelenkoers. Op basis van de betalingsgeschiedenis wordt de volgende ex-dividenddatum verwacht rond 09.03.2027. Ononderbroken dividendgeschiedenis: 20 jaar.
| Ex-datum | Uitbetaling | Bedrag | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-03-10 | — | 3.9091 EUR | 3.1/3.1 % | jaarlijks | XETRA:NOT |
| 2025-03-11 | — | 3.6978 EUR | 2.9/2.9 % | jaarlijks | XETRA:NOT |
Nieuws deze week
Nog geen nieuws van de website van het bedrijf.
Grootste aandeelhouders
| Houder | Belang | Aandelen | Rapportdatum |
|---|---|---|---|
| VANGUARD STAR FUNDS-Vang… | 1.35% | 27.43 mln. | 2026-07-31 |
| VANGUARD TAX-MANAGED FUN… | 0.9% | 18.24 mln. | 2026-06-30 |
| Fisher Asset Management,… | 0.76% | 15.52 mln. | 2026-06-30 |
| iShares Trust-iShares Co… | 0.67% | 13.69 mln. | 2026-08-31 |
| Goldman Sachs TRT II-Gol… | 0.6% | 12.19 mln. | 2026-07-31 |
| Artisan Partners Funds I… | 0.51% | 10.29 mln. | 2026-06-30 |
| Dodge & Cox Funds-Dodge… | 0.44% | 8.9 mln. | 2026-06-30 |
| Morgan Stanley | 0.43% | 8.73 mln. | 2026-06-30 |
| Dimensional Fund Advisor… | 0.4% | 8.12 mln. | 2026-06-30 |
| Fidelity Concord Street… | 0.35% | 7.12 mln. | 2026-07-31 |
| Primecap Management Comp… | 0.32% | 6.59 mln. | 2026-06-30 |
| iShares Trust-iShares MS… | 0.32% | 6.53 mln. | 2026-08-31 |
| LOOMIS SAYLES & CO L P | 0.26% | 5.24 mln. | 2026-06-30 |
| MFS Series Trust XVII-MF… | 0.26% | 5.22 mln. | 2026-06-30 |
| Bank of America Corporat… | 0.24% | 4.91 mln. | 2026-06-30 |
| VANGUARD SPECIALIZED FUN… | 0.23% | 4.66 mln. | 2026-07-31 |
| VANGUARD CHESTER FUNDS-V… | 0.21% | 4.25 mln. | 2026-06-30 |
| Franklin Resources, Inc. | 0.16% | 3.25 mln. | 2026-06-30 |
| Blackrock Inc. | 0.15% | 3.05 mln. | 2026-06-30 |
| Goldman Sachs Group Inc | 0.15% | 2.98 mln. | 2026-06-30 |
| Northern Trust Corporati… | 0.14% | 2.79 mln. | 2026-06-30 |
| DFA INVESTMENT DIMENSION… | 0.11% | 2.14 mln. | 2026-04-30 |
| LOOMIS SAYLES FUNDS II-L… | 0.07% | 1.42 mln. | 2026-06-30 |
| VANGUARD HORIZON FUNDS-V… | 0.06% | 1.21 mln. | 2026-06-30 |
| Franklin Mutual Series F… | 0.06% | 1.19 mln. | 2026-06-30 |
| JANUS INVESTMENT FUND-Ja… | 0.05% | 949 726 | 2026-06-30 |
| Principal Funds, Inc-Equ… | 0.05% | 945 091 | 2026-04-30 |
| Dimensional ETF Trust-Di… | 0.04% | 888 855 | 2026-04-30 |
| Franklin Mutual Series F… | 0.04% | 812 618 | 2026-06-30 |
| Dimensional ETF Trust-Di… | 0.04% | 716 836 | 2026-04-30 |
| Pacer Advisors, Inc. | 0.02% | 482 153 | 2026-06-30 |
| Partners Capital Investm… | 0% | 24 335 | 2026-06-30 |
| Paradigm Asset Managemen… | 0% | 21 514 | 2026-06-30 |
| Generali Investments Cee… | 0% | 15 729 | 2026-06-30 |
